Skip to main content
Erschienen in: Journal of Gastrointestinal Surgery 1/2011

01.01.2011 | Original Article

Detection of Lymph Node Involvement by Cytokeratin Immunohistochemistry is an Independent Prognostic Factor After Curative Resection of Esophageal Cancer

verfasst von: Goran Marjanovic, Markus Schricker, Axel Walch, Axel zur Hausen, Ulrich T. Hopt, Andreas Imdahl, Frank Makowiec

Erschienen in: Journal of Gastrointestinal Surgery | Ausgabe 1/2011

Einloggen, um Zugang zu erhalten

Abstract

Background

Involved lymph nodes (LN) are a negative prognostic factor in esophageal cancers. To assess the role of nodal micrometastases, we performed immunohistochemical analyses of LN after resection of node-negative esophageal cancers and correlated the results with survival.

Methods

Seventy patients with esophageal cancer after curative resection and conventionally negative nodes were included. The LN were examined with six consecutive sections (three hematoxylin and eosin (HE) stained and three stained immunohistochemically with the cytokeratin (CK) antibodies AE1/AE3). Survival was evaluated uni- and multivariately. Median follow-up was 4.1 years.

Results

Immunohistochemical analysis showed CK-positive LN in 16 (23%) patients. Of those 16 cases with CK-positive LN, nine had aviable macrometastases, ten had CK-positive scars/fibrosis and five had viable micrometastases. All patients with aviable macrometastases or CK-positive scars/fibrosis had undergone neoadjuvant chemoradiation. Five-year survival was 48% in all patients. In univariate analysis, survival was worse in patients with CK-positive LN (5-year survival of 30% vs. 54% in CK-negative LN; p < 0.02) and in patients with squamous cell carcinoma (5-year survival of 38% vs. 75% in adenocarcinoma; p = 0.05). Multivariate analysis revealed CK-positive LN (p = 0.02) and (borderline) squamous cell carcinoma (p = 0.06) as negative prognostic factors.

Conclusions

The immunohistochemical analysis of LN may detect (viable or non-viable) tumor cells in lymph nodes after resection of conventionally node-negative esophageal cancers. Conventional pathological analysis by HE, therefore, understages esophageal cancer in these cases. The detection of CK-positive cells in resected LN is an independent prognostic factor in otherwise LN-negative esophageal cancer.
Literatur
1.
Zurück zum Zitat Gee DW and Rattner DW. Management of gastroesophageal tumors. Oncologist 2007; 12(2): 175-85.PubMedCrossRef Gee DW and Rattner DW. Management of gastroesophageal tumors. Oncologist 2007; 12(2): 175-85.PubMedCrossRef
2.
Zurück zum Zitat Hosch SB, Stoecklein NH, Pichlmeier U, Rehders A, Scheunemann P, Niendorf A, Knoefel WT, and Izbicki JR. Esophageal cancer: the mode of lymphatic tumor cell spread and its prognostic significance. J Clin Oncol 2001; 19(7): 1970-5.PubMed Hosch SB, Stoecklein NH, Pichlmeier U, Rehders A, Scheunemann P, Niendorf A, Knoefel WT, and Izbicki JR. Esophageal cancer: the mode of lymphatic tumor cell spread and its prognostic significance. J Clin Oncol 2001; 19(7): 1970-5.PubMed
3.
Zurück zum Zitat Xiao ZF, Yang ZY, Miao YJ, Wang LH, Yin WB, Gu XZ, Zhang DC, Sun KL, Chen GY, and He J. Influence of number of metastatic lymph nodes on survival of curative resected thoracic esophageal cancer patients and value of radiotherapy: report of 549 cases. Int J Radiat Oncol Biol Phys 2005; 62(1): 82-90.PubMedCrossRef Xiao ZF, Yang ZY, Miao YJ, Wang LH, Yin WB, Gu XZ, Zhang DC, Sun KL, Chen GY, and He J. Influence of number of metastatic lymph nodes on survival of curative resected thoracic esophageal cancer patients and value of radiotherapy: report of 549 cases. Int J Radiat Oncol Biol Phys 2005; 62(1): 82-90.PubMedCrossRef
4.
Zurück zum Zitat Stein HJ, Feith M, Bruecher BL, Naehrig J, Sarbia M, and Siewert JR. Early esophageal cancer: pattern of lymphatic spread and prognostic factors for long-term survival after surgical resection. Ann Surg 2005; 242(4): 566-73; discussion 573-5.PubMed Stein HJ, Feith M, Bruecher BL, Naehrig J, Sarbia M, and Siewert JR. Early esophageal cancer: pattern of lymphatic spread and prognostic factors for long-term survival after surgical resection. Ann Surg 2005; 242(4): 566-73; discussion 573-5.PubMed
5.
Zurück zum Zitat Lerut T, Nafteux P, Moons J, Coosemans W, Decker G, De Leyn P, Van Raemdonck D, and Ectors N. Three-field lymphadenectomy for carcinoma of the esophagus and gastroesophageal junction in 174 R0 resections: impact on staging, disease-free survival, and outcome: a plea for adaptation of TNM classification in upper-half esophageal carcinoma. Ann Surg 2004; 240(6): 962-72; discussion 972-4.PubMedCrossRef Lerut T, Nafteux P, Moons J, Coosemans W, Decker G, De Leyn P, Van Raemdonck D, and Ectors N. Three-field lymphadenectomy for carcinoma of the esophagus and gastroesophageal junction in 174 R0 resections: impact on staging, disease-free survival, and outcome: a plea for adaptation of TNM classification in upper-half esophageal carcinoma. Ann Surg 2004; 240(6): 962-72; discussion 972-4.PubMedCrossRef
6.
Zurück zum Zitat Chen G, Wang Z, Liu XY, and Liu FY. Recurrence pattern of squamous cell carcinoma in the middle thoracic esophagus after modified Ivor–Lewis esophagectomy. World J Surg 2007; 31(5): 1107-14.PubMedCrossRef Chen G, Wang Z, Liu XY, and Liu FY. Recurrence pattern of squamous cell carcinoma in the middle thoracic esophagus after modified Ivor–Lewis esophagectomy. World J Surg 2007; 31(5): 1107-14.PubMedCrossRef
7.
Zurück zum Zitat Law SY, Fok M, and Wong J. Pattern of recurrence after oesophageal resection for cancer: clinical implications. Br J Surg 1996; 83(1): 107-11.PubMedCrossRef Law SY, Fok M, and Wong J. Pattern of recurrence after oesophageal resection for cancer: clinical implications. Br J Surg 1996; 83(1): 107-11.PubMedCrossRef
8.
Zurück zum Zitat Mariette C, Taillier G, Van Seuningen I, and Triboulet JP. Factors affecting postoperative course and survival after en bloc resection for esophageal carcinoma. Ann Thorac Surg 2004; 78(4): 1177-83.PubMedCrossRef Mariette C, Taillier G, Van Seuningen I, and Triboulet JP. Factors affecting postoperative course and survival after en bloc resection for esophageal carcinoma. Ann Thorac Surg 2004; 78(4): 1177-83.PubMedCrossRef
9.
Zurück zum Zitat Keene SA and Demeure MJ. The clinical significance of micrometastases and molecular metastases. Surgery 2001; 129(1): 1-5.PubMedCrossRef Keene SA and Demeure MJ. The clinical significance of micrometastases and molecular metastases. Surgery 2001; 129(1): 1-5.PubMedCrossRef
10.
Zurück zum Zitat Hermanek P, Hutter RV, Sobin LH, and Wittekind C. International Union Against Cancer. Classification of isolated tumor cells and micrometastasis. Cancer 1999; 86(12): 2668-73. Hermanek P, Hutter RV, Sobin LH, and Wittekind C. International Union Against Cancer. Classification of isolated tumor cells and micrometastasis. Cancer 1999; 86(12): 2668-73.
11.
Zurück zum Zitat Tseng SC, Jarvinen MJ, Nelson WG, Huang JW, Woodcock-Mitchell J, and Sun TT. Correlation of specific keratins with different types of epithelial differentiation: monoclonal antibody studies. Cell 1982; 30(2): 361-72.PubMedCrossRef Tseng SC, Jarvinen MJ, Nelson WG, Huang JW, Woodcock-Mitchell J, and Sun TT. Correlation of specific keratins with different types of epithelial differentiation: monoclonal antibody studies. Cell 1982; 30(2): 361-72.PubMedCrossRef
12.
Zurück zum Zitat Glickman JN, Torres C, Wang HH, Turner JR, Shahsafaei A, Richards WG, Sugarbaker DJ, and Odze RD. The prognostic significance of lymph node micrometastasis in patients with esophageal carcinoma. Cancer 1999; 85(4): 769-78.PubMedCrossRef Glickman JN, Torres C, Wang HH, Turner JR, Shahsafaei A, Richards WG, Sugarbaker DJ, and Odze RD. The prognostic significance of lymph node micrometastasis in patients with esophageal carcinoma. Cancer 1999; 85(4): 769-78.PubMedCrossRef
13.
Zurück zum Zitat Izbicki JR, Hosch SB, Pichlmeier U, Rehders A, Busch C, Niendorf A, Passlick B, Broelsch CE, and Pantel K. Prognostic value of immunohistochemically identifiable tumor cells in lymph nodes of patients with completely resected esophageal cancer. N Engl J Med 1997; 337(17): 1188-94.PubMedCrossRef Izbicki JR, Hosch SB, Pichlmeier U, Rehders A, Busch C, Niendorf A, Passlick B, Broelsch CE, and Pantel K. Prognostic value of immunohistochemically identifiable tumor cells in lymph nodes of patients with completely resected esophageal cancer. N Engl J Med 1997; 337(17): 1188-94.PubMedCrossRef
14.
Zurück zum Zitat Komukai S, Nishimaki T, Watanabe H, Ajioka Y, Suzuki T, and Hatakeyama K. Significance of immunohistochemically demonstrated micrometastases to lymph nodes in esophageal cancer with histologically negative nodes. Surgery 2000; 127(1): 40-6.PubMedCrossRef Komukai S, Nishimaki T, Watanabe H, Ajioka Y, Suzuki T, and Hatakeyama K. Significance of immunohistochemically demonstrated micrometastases to lymph nodes in esophageal cancer with histologically negative nodes. Surgery 2000; 127(1): 40-6.PubMedCrossRef
15.
Zurück zum Zitat Natsugoe S, Mueller J, Stein HJ, Feith M, Hofler H, and Siewert JR. Micrometastasis and tumor cell microinvolvement of lymph nodes from esophageal squamous cell carcinoma: frequency, associated tumor characteristics, and impact on prognosis. Cancer 1998; 83(5): 858-66.PubMedCrossRef Natsugoe S, Mueller J, Stein HJ, Feith M, Hofler H, and Siewert JR. Micrometastasis and tumor cell microinvolvement of lymph nodes from esophageal squamous cell carcinoma: frequency, associated tumor characteristics, and impact on prognosis. Cancer 1998; 83(5): 858-66.PubMedCrossRef
16.
Zurück zum Zitat Sato F, Shimada Y, Li Z, Watanabe G, Maeda M, and Imamura M. Lymph node micrometastasis and prognosis in patients with oesophageal squamous cell carcinoma. Br J Surg 2001; 88(3): 426-32.PubMedCrossRef Sato F, Shimada Y, Li Z, Watanabe G, Maeda M, and Imamura M. Lymph node micrometastasis and prognosis in patients with oesophageal squamous cell carcinoma. Br J Surg 2001; 88(3): 426-32.PubMedCrossRef
17.
Zurück zum Zitat Tanabe T, Nishimaki T, Watanabe H, Ajioka Y, Akazawa K, Komukai S, and Hatakeyama K. Immunohistochemically detected micrometastasis in lymph nodes from superficial esophageal squamous cell carcinoma. J Surg Oncol 2003; 82(3): 153-9.PubMedCrossRef Tanabe T, Nishimaki T, Watanabe H, Ajioka Y, Akazawa K, Komukai S, and Hatakeyama K. Immunohistochemically detected micrometastasis in lymph nodes from superficial esophageal squamous cell carcinoma. J Surg Oncol 2003; 82(3): 153-9.PubMedCrossRef
18.
Zurück zum Zitat Waterman TA, Hagen JA, Peters JH, DeMeester SR, Taylor CR, and Demeester TR. The prognostic importance of immunohistochemically detected node metastases in resected esophageal adenocarcinoma. Ann Thorac Surg 2004; 78(4): 1161-9; discussion 1161-9.PubMedCrossRef Waterman TA, Hagen JA, Peters JH, DeMeester SR, Taylor CR, and Demeester TR. The prognostic importance of immunohistochemically detected node metastases in resected esophageal adenocarcinoma. Ann Thorac Surg 2004; 78(4): 1161-9; discussion 1161-9.PubMedCrossRef
19.
Zurück zum Zitat O’Sullivan GC, Sheehan D, Clarke A, Stuart R, Kelly J, Kiely MD, Walsh T, Collins JK, and Shanahan F. Micrometastases in esophagogastric cancer: high detection rate in resected rib segments. Gastroenterology 1999; 116(3): 543-8.PubMedCrossRef O’Sullivan GC, Sheehan D, Clarke A, Stuart R, Kelly J, Kiely MD, Walsh T, Collins JK, and Shanahan F. Micrometastases in esophagogastric cancer: high detection rate in resected rib segments. Gastroenterology 1999; 116(3): 543-8.PubMedCrossRef
20.
Zurück zum Zitat Doki Y, Ishikawa O, Mano M, Hiratsuka M, Sasaki Y, Kameyama M, Ohigashi H, Murata K, Yamada T, Miyashiro I, Yokoyama S, Ishiguro S, and Imaoka S. Cytokeratin deposits in lymph nodes show distinct clinical significance from lymph node micrometastasis in human esophageal cancers. J Surg Res 2002; 107(1): 75-81.PubMed Doki Y, Ishikawa O, Mano M, Hiratsuka M, Sasaki Y, Kameyama M, Ohigashi H, Murata K, Yamada T, Miyashiro I, Yokoyama S, Ishiguro S, and Imaoka S. Cytokeratin deposits in lymph nodes show distinct clinical significance from lymph node micrometastasis in human esophageal cancers. J Surg Res 2002; 107(1): 75-81.PubMed
21.
Zurück zum Zitat Imdahl A, Schoffel U, Ruf G, and Hopf UT. [Preoperative chemoradiation in esophageal cancer: experience of a single center in 102 patients]. Zentralbl Chir 2004; 129(5): 350-5.PubMedCrossRef Imdahl A, Schoffel U, Ruf G, and Hopf UT. [Preoperative chemoradiation in esophageal cancer: experience of a single center in 102 patients]. Zentralbl Chir 2004; 129(5): 350-5.PubMedCrossRef
22.
Zurück zum Zitat Bosset JF, Gignoux M, Triboulet JP, Tiret E, Mantion G, Elias D, Lozach P, Ollier JC, Pavy JJ, Mercier M, and Sahmoud T. Chemoradiotherapy followed by surgery compared with surgery alone in squamous-cell cancer of the esophagus. N Engl J Med 1997; 337(3): 161-7.PubMedCrossRef Bosset JF, Gignoux M, Triboulet JP, Tiret E, Mantion G, Elias D, Lozach P, Ollier JC, Pavy JJ, Mercier M, and Sahmoud T. Chemoradiotherapy followed by surgery compared with surgery alone in squamous-cell cancer of the esophagus. N Engl J Med 1997; 337(3): 161-7.PubMedCrossRef
23.
Zurück zum Zitat Naunheim KS, Petruska PJ, Roy TS, Schlueter JM, Kim H, and Baue AE. Multimodality therapy for adenocarcinoma of the esophagus. Ann Thorac Surg 1995; 59(5): 1085-90; discussion 1090-1.PubMedCrossRef Naunheim KS, Petruska PJ, Roy TS, Schlueter JM, Kim H, and Baue AE. Multimodality therapy for adenocarcinoma of the esophagus. Ann Thorac Surg 1995; 59(5): 1085-90; discussion 1090-1.PubMedCrossRef
24.
Zurück zum Zitat Hosch SB, Steffani KD, Scheunemann P, and Izbicki JR. Micrometastases from HBP malignancies and metastatic cancer. J Hepatobiliary Pancreat Surg 2002; 9(5): 583-91.PubMedCrossRef Hosch SB, Steffani KD, Scheunemann P, and Izbicki JR. Micrometastases from HBP malignancies and metastatic cancer. J Hepatobiliary Pancreat Surg 2002; 9(5): 583-91.PubMedCrossRef
25.
Zurück zum Zitat Kaifi JT, Reichelt U, Quaas A, Schurr PG, Wachowiak R, Yekebas EF, Strate T, Schneider C, Pantel K, Schachner M, Sauter G, and Izbicki JR. L1 is associated with micrometastatic spread and poor outcome in colorectal cancer. Mod Pathol 2007; 20(11): 1183-90.PubMedCrossRef Kaifi JT, Reichelt U, Quaas A, Schurr PG, Wachowiak R, Yekebas EF, Strate T, Schneider C, Pantel K, Schachner M, Sauter G, and Izbicki JR. L1 is associated with micrometastatic spread and poor outcome in colorectal cancer. Mod Pathol 2007; 20(11): 1183-90.PubMedCrossRef
26.
Zurück zum Zitat Kanemitsu K, Hiraoka T, Tsuji T, Inoue K, and Takamori H. Implication of micrometastases of lymph nodes in patients with extended operation for pancreatic cancer. Pancreas 2003; 26(4): 315-21.PubMedCrossRef Kanemitsu K, Hiraoka T, Tsuji T, Inoue K, and Takamori H. Implication of micrometastases of lymph nodes in patients with extended operation for pancreatic cancer. Pancreas 2003; 26(4): 315-21.PubMedCrossRef
27.
Zurück zum Zitat Izbicki JR, Passlick B, Hosch SB, Kubuschock B, Schneider C, Busch C, Knoefel WT, Thetter O, and Pantel K. Mode of spread in the early phase of lymphatic metastasis in non-small-cell lung cancer: significance of nodal micrometastasis. J Thorac Cardiovasc Surg 1996; 112(3): 623-30.PubMedCrossRef Izbicki JR, Passlick B, Hosch SB, Kubuschock B, Schneider C, Busch C, Knoefel WT, Thetter O, and Pantel K. Mode of spread in the early phase of lymphatic metastasis in non-small-cell lung cancer: significance of nodal micrometastasis. J Thorac Cardiovasc Surg 1996; 112(3): 623-30.PubMedCrossRef
28.
Zurück zum Zitat Passlick B, Izbicki JR, Kubuschok B, Thetter O, and Pantel K. Detection of disseminated lung cancer cells in lymph nodes: impact on staging and prognosis. Ann Thorac Surg 1996; 61(1): 177-82; discussion 183.PubMedCrossRef Passlick B, Izbicki JR, Kubuschok B, Thetter O, and Pantel K. Detection of disseminated lung cancer cells in lymph nodes: impact on staging and prognosis. Ann Thorac Surg 1996; 61(1): 177-82; discussion 183.PubMedCrossRef
29.
Zurück zum Zitat Gillanders WE, Mikhitarian K, Hebert R, Mauldin PD, Palesch Y, Walters C, Urist MM, Mann GB, Doherty G, Herrmann VM, Hill AD, Eremin O, El-Sheemy M, Orr RK, Valle AA, Henderson MA, Dewitty RL, Sugg SL, Frykberg E, Yeh K, Bell RM, Metcalf JS, Elliott BM, Brothers T, Robison J, Mitas M, and Cole DJ. Molecular detection of micrometastatic breast cancer in histopathology-negative axillary lymph nodes correlates with traditional predictors of prognosis: an interim analysis of a prospective multi-institutional cohort study. Ann Surg 2004; 239(6): 828-37; discussion 837-40.PubMedCrossRef Gillanders WE, Mikhitarian K, Hebert R, Mauldin PD, Palesch Y, Walters C, Urist MM, Mann GB, Doherty G, Herrmann VM, Hill AD, Eremin O, El-Sheemy M, Orr RK, Valle AA, Henderson MA, Dewitty RL, Sugg SL, Frykberg E, Yeh K, Bell RM, Metcalf JS, Elliott BM, Brothers T, Robison J, Mitas M, and Cole DJ. Molecular detection of micrometastatic breast cancer in histopathology-negative axillary lymph nodes correlates with traditional predictors of prognosis: an interim analysis of a prospective multi-institutional cohort study. Ann Surg 2004; 239(6): 828-37; discussion 837-40.PubMedCrossRef
30.
Zurück zum Zitat Pantel K, Schlimok G, Angstwurm M, Weckermann D, Schmaus W, Gath H, Passlick B, Izbicki JR, and Riethmuller G. Methodological analysis of immunocytochemical screening for disseminated epithelial tumor cells in bone marrow. J Hematother 1994; 3(3): 165-73.PubMedCrossRef Pantel K, Schlimok G, Angstwurm M, Weckermann D, Schmaus W, Gath H, Passlick B, Izbicki JR, and Riethmuller G. Methodological analysis of immunocytochemical screening for disseminated epithelial tumor cells in bone marrow. J Hematother 1994; 3(3): 165-73.PubMedCrossRef
31.
Zurück zum Zitat Yekebas EF, Schurr PG, Kaifi JT, Link BC, Kutup A, Mann O, Wolfram L, and Izbicki JR. Effectiveness of radical en-bloc-esophagectomy compared to transhiatal esophagectomy in squamous cell cancer of the esophagus is influenced by nodal micrometastases. J Surg Oncol 2006; 93(7): 541-9.PubMedCrossRef Yekebas EF, Schurr PG, Kaifi JT, Link BC, Kutup A, Mann O, Wolfram L, and Izbicki JR. Effectiveness of radical en-bloc-esophagectomy compared to transhiatal esophagectomy in squamous cell cancer of the esophagus is influenced by nodal micrometastases. J Surg Oncol 2006; 93(7): 541-9.PubMedCrossRef
32.
Zurück zum Zitat Jiao X, Eslami A, Ioffe O, Kwong KF, Henry M, Zeng Q, Refaely Y, Burrows W, Gamliel Z, and Krasna MJ. Immunohistochemistry analysis of micrometastasis in pretreatment lymph nodes from patients with esophageal cancer. Ann Thorac Surg 2003; 76(4): 996-9; discussion 999-1000.PubMedCrossRef Jiao X, Eslami A, Ioffe O, Kwong KF, Henry M, Zeng Q, Refaely Y, Burrows W, Gamliel Z, and Krasna MJ. Immunohistochemistry analysis of micrometastasis in pretreatment lymph nodes from patients with esophageal cancer. Ann Thorac Surg 2003; 76(4): 996-9; discussion 999-1000.PubMedCrossRef
33.
Zurück zum Zitat Bonavina L, Soligo D, Quirici N, Bossolasco P, Cesana B, Lembertenghi Deliliers G, and Peracchia A. Bone marrow-disseminated tumor cells in patients with carcinoma of the esophagus or cardia. Surgery 2001; 129(1): 15-22.PubMed Bonavina L, Soligo D, Quirici N, Bossolasco P, Cesana B, Lembertenghi Deliliers G, and Peracchia A. Bone marrow-disseminated tumor cells in patients with carcinoma of the esophagus or cardia. Surgery 2001; 129(1): 15-22.PubMed
34.
Zurück zum Zitat Heeren PA, Kelder W, Blondeel I, van Westreenen HL, Hollema H, and Plukker JT. Prognostic value of nodal micrometastases in patients with cancer of the gastro-oesophageal junction. Eur J Surg Oncol 2005; 31(3): 270-6.PubMedCrossRef Heeren PA, Kelder W, Blondeel I, van Westreenen HL, Hollema H, and Plukker JT. Prognostic value of nodal micrometastases in patients with cancer of the gastro-oesophageal junction. Eur J Surg Oncol 2005; 31(3): 270-6.PubMedCrossRef
35.
Zurück zum Zitat Vazquez-Sequeiros E, Wang L, Burgart L, Harmsen W, Zinsmeister A, Allen M, Jondal M, and Wiersema M. Occult lymph node metastases as a predictor of tumor relapse in patients with node-negative esophageal carcinoma. Gastroenterology 2002; 122(7): 1815-21.PubMedCrossRef Vazquez-Sequeiros E, Wang L, Burgart L, Harmsen W, Zinsmeister A, Allen M, Jondal M, and Wiersema M. Occult lymph node metastases as a predictor of tumor relapse in patients with node-negative esophageal carcinoma. Gastroenterology 2002; 122(7): 1815-21.PubMedCrossRef
36.
Zurück zum Zitat Matsumoto M, Natsugoe S, Nakashima S, Sakamoto F, Okumura H, Sakita H, Baba M, Takao S, and Aikou T. Clinical significance of lymph node micrometastasis of pN0 esophageal squamous cell carcinoma. Cancer Lett 2000; 153(1-2): 189-97.PubMedCrossRef Matsumoto M, Natsugoe S, Nakashima S, Sakamoto F, Okumura H, Sakita H, Baba M, Takao S, and Aikou T. Clinical significance of lymph node micrometastasis of pN0 esophageal squamous cell carcinoma. Cancer Lett 2000; 153(1-2): 189-97.PubMedCrossRef
37.
Zurück zum Zitat Matsuyama J, Doki Y, Yasuda T, Miyata H, Fujiwara Y, Takiguchi S, Yamasaki M, Makari Y, Matsuura N, Mano M, and Monden M. The effect of neoadjuvant chemotherapy on lymph node micrometastases in squamous cell carcinomas of the thoracic esophagus. Surgery 2007; 141(5): 570-80.PubMedCrossRef Matsuyama J, Doki Y, Yasuda T, Miyata H, Fujiwara Y, Takiguchi S, Yamasaki M, Makari Y, Matsuura N, Mano M, and Monden M. The effect of neoadjuvant chemotherapy on lymph node micrometastases in squamous cell carcinomas of the thoracic esophagus. Surgery 2007; 141(5): 570-80.PubMedCrossRef
38.
Zurück zum Zitat Fiorica F, Di Bona D, Schepis F, Licata A, Shahied L, Venturi A, Falchi AM, Craxi A, and Camma C. Preoperative chemoradiotherapy for oesophageal cancer: a systematic review and meta-analysis. Gut 2004; 53(7): 925-30.PubMedCrossRef Fiorica F, Di Bona D, Schepis F, Licata A, Shahied L, Venturi A, Falchi AM, Craxi A, and Camma C. Preoperative chemoradiotherapy for oesophageal cancer: a systematic review and meta-analysis. Gut 2004; 53(7): 925-30.PubMedCrossRef
39.
Zurück zum Zitat Urschel JD and Vasan H. A meta-analysis of randomized controlled trials that compared neoadjuvant chemoradiation and surgery to surgery alone for resectable esophageal cancer. Am J Surg 2003; 185(6): 538-43.PubMedCrossRef Urschel JD and Vasan H. A meta-analysis of randomized controlled trials that compared neoadjuvant chemoradiation and surgery to surgery alone for resectable esophageal cancer. Am J Surg 2003; 185(6): 538-43.PubMedCrossRef
40.
Zurück zum Zitat Kaklamanos IG, Walker GR, Ferry K, Franceschi D, and Livingstone AS. Neoadjuvant treatment for resectable cancer of the esophagus and the gastroesophageal junction: a meta-analysis of randomized clinical trials. Ann Surg Oncol 2003; 10(7): 754-61.PubMedCrossRef Kaklamanos IG, Walker GR, Ferry K, Franceschi D, and Livingstone AS. Neoadjuvant treatment for resectable cancer of the esophagus and the gastroesophageal junction: a meta-analysis of randomized clinical trials. Ann Surg Oncol 2003; 10(7): 754-61.PubMedCrossRef
41.
Zurück zum Zitat Imdahl A, Schoffel U, and Ruf G. Impact of neoadjuvant therapy of perioperative morbidity in patients with esophageal cancer. Am J Surg 2004; 187(1): 64-8.PubMedCrossRef Imdahl A, Schoffel U, and Ruf G. Impact of neoadjuvant therapy of perioperative morbidity in patients with esophageal cancer. Am J Surg 2004; 187(1): 64-8.PubMedCrossRef
42.
Zurück zum Zitat Berger AC, Farma J, Scott WJ, Freedman G, Weiner L, Cheng JD, Wang H, and Goldberg M. Complete response to neoadjuvant chemoradiotherapy in esophageal carcinoma is associated with significantly improved survival. J Clin Oncol 2005; 23(19): 4330-7.PubMedCrossRef Berger AC, Farma J, Scott WJ, Freedman G, Weiner L, Cheng JD, Wang H, and Goldberg M. Complete response to neoadjuvant chemoradiotherapy in esophageal carcinoma is associated with significantly improved survival. J Clin Oncol 2005; 23(19): 4330-7.PubMedCrossRef
Metadaten
Titel
Detection of Lymph Node Involvement by Cytokeratin Immunohistochemistry is an Independent Prognostic Factor After Curative Resection of Esophageal Cancer
verfasst von
Goran Marjanovic
Markus Schricker
Axel Walch
Axel zur Hausen
Ulrich T. Hopt
Andreas Imdahl
Frank Makowiec
Publikationsdatum
01.01.2011
Verlag
Springer-Verlag
Erschienen in
Journal of Gastrointestinal Surgery / Ausgabe 1/2011
Print ISSN: 1091-255X
Elektronische ISSN: 1873-4626
DOI
https://doi.org/10.1007/s11605-010-1359-8

Weitere Artikel der Ausgabe 1/2011

Journal of Gastrointestinal Surgery 1/2011 Zur Ausgabe

Update Chirurgie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

S3-Leitlinie „Diagnostik und Therapie des Karpaltunnelsyndroms“

CME: 2 Punkte

Prof. Dr. med. Gregor Antoniadis Das Karpaltunnelsyndrom ist die häufigste Kompressionsneuropathie peripherer Nerven. Obwohl die Anamnese mit dem nächtlichen Einschlafen der Hand (Brachialgia parästhetica nocturna) sehr typisch ist, ist eine klinisch-neurologische Untersuchung und Elektroneurografie in manchen Fällen auch eine Neurosonografie erforderlich. Im Anfangsstadium sind konservative Maßnahmen (Handgelenksschiene, Ergotherapie) empfehlenswert. Bei nicht Ansprechen der konservativen Therapie oder Auftreten von neurologischen Ausfällen ist eine Dekompression des N. medianus am Karpaltunnel indiziert.

Prof. Dr. med. Gregor Antoniadis
Berufsverband der Deutschen Chirurgie e.V.

S2e-Leitlinie „Distale Radiusfraktur“

CME: 2 Punkte

Dr. med. Benjamin Meyknecht, PD Dr. med. Oliver Pieske Das Webinar S2e-Leitlinie „Distale Radiusfraktur“ beschäftigt sich mit Fragen und Antworten zu Diagnostik und Klassifikation sowie Möglichkeiten des Ausschlusses von Zusatzverletzungen. Die Referenten erläutern, welche Frakturen konservativ behandelt werden können und wie. Das Webinar beantwortet die Frage nach aktuellen operativen Therapiekonzepten: Welcher Zugang, welches Osteosynthesematerial? Auf was muss bei der Nachbehandlung der distalen Radiusfraktur geachtet werden?

PD Dr. med. Oliver Pieske
Dr. med. Benjamin Meyknecht
Berufsverband der Deutschen Chirurgie e.V.

S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“

CME: 2 Punkte

Dr. med. Mihailo Andric
Inhalte des Webinars zur S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“ sind die Darstellung des Projektes und des Erstellungswegs zur S1-Leitlinie, die Erläuterung der klinischen Relevanz der Klassifikation EAES 2015, die wissenschaftliche Begründung der wichtigsten Empfehlungen und die Darstellung stadiengerechter Therapieoptionen.

Dr. med. Mihailo Andric
Berufsverband der Deutschen Chirurgie e.V.